SecBot SecBot
8-K ·Filed Nov 4, 2026

MCK

MCKESSON CORP
BULLISH
Impact 6/10
Horizonweeks Processed12d 5h ago SEC0000927653-26-000279
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised guidance and strong beat across all segments signal sustained momentum. Watch for closing of the Option Care Health investment and further capital deployment updates on the earnings call.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$1,072.00
T+0 close · Nov 4, 2026 · via day close
Latest settled
+0.47%
T+5 · $1,077.05 · next T+20 in 17d
Vs SPY
−2.82%
α at T+5
Latest observation
+6.22%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $1,072.00entry
  2. T+1 · 11d ago −1.04%α −1.35% · $1,060.84
  3. T+5 · 5d ago +0.47%α −2.82% · $1,077.05
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

McKesson reported fiscal Q2 2027 revenue of $111.0B (+8% YoY) and adjusted EPS of $11.68 (+18% YoY), beating the consensus estimate of $10.75. The company raised its full-year adjusted EPS guidance to $45.60-$46.40 from $44.20-$45.00, citing strong operational performance across segments.

Key Financial Metrics

EPS (Adj.)
$11.68
est $10.75 · +8.7% · GAAP: $10.44
Revenue
$111.0B
est $110.0B · +0.9% · +8.0% YoY
Rating
beat
Free Cash Flow
$2.6B

Key Facts

  • Q2 FY2027 revenue $110.96B, +8% YoY vs $103.15B
  • Q2 GAAP diluted EPS $10.44 vs $8.92 YoY, +17%
  • Q2 adjusted diluted EPS $11.68 vs $9.86 YoY, +18%
  • Adjusted EPS beat consensus of $10.75 by 8.7%
  • Full-year adjusted EPS guidance raised to $45.60-$46.40 from $44.20-$45.00
  • North American Pharmaceutical segment adjusted operating profit +22% YoY
  • Oncology Multispecialty segment revenue +24% YoY
  • Generated $3.1B operating cash flow and $2.9B free cash flow in Q2
  • Returned $3.6B to shareholders YTD via buybacks and dividends
  • Signed agreement to extend CVS Health distribution partnership through 2032
  • Completed acquisition of Precision Medicine Group on Nov 2, 2026
  • Signed $1.4B deal for ~49% minority stake in Option Care Health

Financial Impact

Q2 adjusted EPS of $11.68 beat consensus of $10.75 by $0.93 (+8.7%); full-year guidance raised by $1.40 at midpoint to $46.00

revenueepsguidanceoperating cash flow

Segment Breakdown

SegmentRevenueGrowth
North American Pharmaceutical$91.4B+6.0%
Oncology Multispecialty$15.0B+24.0%
Prescription Technology Solutions$1.5B+10.0%
Medical-Surgical Solutions$3.1B+5.0%

Risk Factors

  • Medical-Surgical Solutions adjusted operating profit declined 10% YoY due to ambulatory care mix
  • Planned separation of Medical-Surgical Solutions and Option Care Health deal subject to regulatory approvals
  • Opioid litigation liabilities remain at $4.6B on the balance sheet

Market Snapshot

Exchange
NYSE
Sector
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Analyst Consensus
82% bullish (22 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000927653-26-000279
Document: mck-20261104.htm0000927653-26-000279
Document: 0000927653-26-000279-index-headers.html0000927653-26-000279
Document: 0000927653-26-000279-index.html0000927653-26-000279
Document: 0000927653-26-000279.txt0000927653-26-000279
8-K Data (Synthetic)0000927653-26-000279

Track record

26 reports on MCK

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +22.92% at T+60 after the Apr 1, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 144 Neutral 2/10 Entry $1,072.00 to $1,077.05 Now $1,102.81 +2.87% ▲ +0.47% −2.82% vs SPY
  2. Nov 4, 202612d ago 144 Neutral 2/10 Entry $1,072.00 to $1,077.05 Now $1,102.81 +2.87% ▲ +0.47% −2.82% vs SPY
  3. Nov 4, 202612d ago 8-K Bullish 6/10 Viewing Entry $1,072.00 to $1,077.05 Now $1,102.81 +2.87% ▲ +0.47% −2.82% vs SPY
  4. Oct 30, 202617d ago 25-NSE Neutral 1/10 Entry $994.58 to $1,060.84 Now $1,102.81 +10.88% ▲ +6.66% +9.37% vs SPY
  5. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $960.56 to $1,069.44 Now $1,102.81 +14.81% ▲ +11.34% +12.05% vs SPY
  6. Oct 27, 202621d ago GOVT-CONTRACT Neutral 3/10 Entry $960.56 to $1,069.44 Now $1,102.81 +14.81% ▲ +11.34% +12.05% vs SPY
  7. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $955.76 to $1,010.43 Now $1,102.81 +15.39% ▲ +5.72% +7.21% vs SPY
  8. Oct 6, 20265w ago 8-K Bullish 6/10 Entry $921.67 to $961.88 Now $1,102.81 +19.65% ▲ +4.36% +4.50% vs SPY
  9. Sep 1, 202611w ago GOVT-CONTRACT Neutral 3/10 Entry $924.78 to $880.86 Now $1,102.81 +19.25% ▼ −4.75% −3.79% vs SPY
  10. Aug 28, 202611w ago 8-K Neutral 4/10 Entry $885.32 to $896.29 Now $1,102.81 +24.57% ▲ +1.24% +1.38% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (12h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026